{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:41:41Z","timestamp":1770752501192,"version":"3.50.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bayer plc, Reading, UK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>This report, based on guidance from a panel of UK retina specialists, introduces a revised intravitreal aflibercept (IVT-AFL) treat-and-extend (T&amp;E) pathway for the treatment of neovascular age-related macular degeneration (nAMD). The T&amp;E pathway incorporates the updated IVT-AFL label (April 2021) allowing flexible treatment intervals of 4 weeks to 16 weeks, after three initiation doses and a further dose after 8 weeks. Practical guidance is provided on the clinical implementation of the revised pathway, with the aim of supporting clinical decision-making to benefit patients and addressing capacity issues in nAMD services.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Three structured round-table meetings of UK retina specialists were held online on 19 May, 16 June and 13 October 2021. These meetings were organised and funded by Bayer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The authors revised the previously published consensus pathway to reflect the changes to the IVT-AFL label and developed guidelines for the implementation of the pathway in UK clinical practice. The guidelines include topics such as recommendations for extending patients with 2- or 4-week adjustments, extending patients to 16-week treatment intervals, managing fellow eye involvement, and reducing treatment intervals for patients with particularly active disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The revised IVT-AFL T&amp;E nAMD pathway offers guidance to clinicians seeking to increase the dosing flexibility of IVT-AFL, with 4- to 16-week treatment intervals, in line with the updated IVT-AFL label, to meet the continually evolving demands of nAMD service provision.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41433-022-02264-3","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T14:05:24Z","timestamp":1665151524000},"page":"1916-1921","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Practical implementation of a q4\u2013q16 aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration: Updated guidance from a UK expert panel"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2141-4512","authenticated-orcid":false,"given":"Clare","family":"Bailey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7213-2537","authenticated-orcid":false,"given":"Peter","family":"Cackett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Kotagiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajjad","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Minos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirodhini","family":"Narendran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Patwardhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6363-7805","authenticated-orcid":false,"given":"Dawn A.","family":"Sim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Morgan-Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"O\u2019Neil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Straw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"key":"2264_CR1","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","volume":"392","author":"P Mitchell","year":"2018","unstructured":"Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392:1147\u201359.","journal-title":"Lancet"},{"key":"2264_CR2","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","volume":"255","author":"P Lanzetta","year":"2017","unstructured":"Lanzetta P, Loewenstein A, Vision Academy Steering Committee. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255:1259\u201373.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2264_CR3","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1136\/bjophthalmol-2020-317434","volume":"105","author":"V Daien","year":"2021","unstructured":"Daien V, Finger RP, Talks JS, Mitchell P, Wong TY, Sakamoto T, et al. Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence. Br J Ophthalmol. 2021;105:1475\u20139.","journal-title":"Br J Ophthalmol"},{"key":"2264_CR4","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s00417-012-2177-3","volume":"251","author":"KM Droege","year":"2013","unstructured":"Droege KM, Muether PS, Hermann MM, Caramoy A, Viebahn U, Kirchhof B, et al. Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life. Graefes Arch Clin Exp Ophthalmol. 2013;251:1281\u20134.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2264_CR5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","volume":"99","author":"FG Holz","year":"2015","unstructured":"Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99:220\u20136.","journal-title":"Br J Ophthalmol"},{"key":"2264_CR6","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1097\/IAE.0000000000003128","volume":"41","author":"P Mitchell","year":"2021","unstructured":"Mitchell P, Holz FG, Hykin P, Midena E, Souied E, Allmeier H, et al. Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: the ARIES study: a randomized clinical trial. Retina. 2021;41:1911\u201320.","journal-title":"Retina"},{"key":"2264_CR7","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.2147\/OPTH.S233061","volume":"14","author":"W Amoaku","year":"2020","unstructured":"Amoaku W, Bailey C, Downey L, Gale RP, Ghanchi F, Hamilton R, et al. Providing a safe and effective intravitreal treatment service: strategies for service delivery. Clin Ophthalmol. 2020;14:1315\u201328.","journal-title":"Clin Ophthalmol"},{"key":"2264_CR8","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y, et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR; a randomized controlled trial. Adv Ther. 2020;37:1173\u201387.","journal-title":"Adv Ther"},{"key":"2264_CR9","unstructured":"Bayer data on file (EYL028). ARIES: Integrated Clinical Study Protocol. No. BAY86-5321\/17508. 2019."},{"key":"2264_CR10","unstructured":"European Medicines Agency. Eylea: EPAR \u2013 Procedural steps taken and scientific information after the authorisation. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/procedural-steps-after\/eylea-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf."},{"key":"2264_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41433-018-0300-3","volume":"33","author":"RP Gale","year":"2019","unstructured":"Gale RP, Mahmood S, Devonport H, Patel PJ, Ross AH, Walters G, et al. Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service. Eye (Lond). 2019;33:1\u201321.","journal-title":"Eye (Lond)"},{"key":"2264_CR12","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/s41433-019-0383-5","volume":"33","author":"JC Buchan","year":"2019","unstructured":"Buchan JC, Norman P, Shickle D, Cassels-Brown A, MacEwen C. Failing to plan and planning to fail. Can we predict the future growth of demand on UK Eye Care Services? Eye (Lond). 2019;33:1029\u201331.","journal-title":"Eye (Lond)"},{"key":"2264_CR13","unstructured":"The Royal College of Ophthalmologists. The Way Forward. Age-Related Macular Degeneration and Diabetic Retinopathy. 2017. https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2015\/10\/RCOphth-The-Way-Forward-AMD-300117.pdf."},{"key":"2264_CR14","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s00417-021-05174-4","volume":"259","author":"LG Stone","year":"2021","unstructured":"Stone LG, Grinton ME, Talks JS. Delayed follow-up of medical retina patients due to COVID-19: impact on disease activity and visual acuity. Graefes Arch Clin Exp Ophthalmol. 2021;259:1773\u201380.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2264_CR15","doi-asserted-by":"publisher","first-page":"n471","DOI":"10.1136\/bmj.n471","volume":"372","author":"J Appleby","year":"2021","unstructured":"Appleby J. NHS sickness absence during the covid-19 pandemic. BMJ. 2021;372:n471.","journal-title":"BMJ"},{"key":"2264_CR16","unstructured":"The Royal College of Ophthalmologists. Guidance on restarting Medical Retina Services. 2020. https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2021\/01\/Guidance-on-restarting-Medial-Retina-Services-1.pdf."},{"key":"2264_CR17","unstructured":"Bayer AG. Eylea 40mg\/mL solution for injection in a vial \u2013 summary of product characteristics. 2021."},{"key":"2264_CR18","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41433-019-0747-x","volume":"34","author":"AH Ross","year":"2020","unstructured":"Ross AH, Downey L, Devonport H, Gale RP, Kotagiri A, Mahmood S, et al. Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration. Eye (Lond). 2020;34:1825\u201334.","journal-title":"Eye (Lond)"},{"key":"2264_CR19","unstructured":"The Royal College of Ophthalmologists. Intravitreal injection therapy. Ophthalmic Service Guidance report. 2018. https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2022\/02\/Intravitreal-Injection-Therapy-August-2018-1.pdf."},{"key":"2264_CR20","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1136\/bjophthalmol-2019-314446","volume":"104","author":"K Fasler","year":"2020","unstructured":"Fasler K, Fu DJ, Moraes G, Wagner S, Gokhale E, Kortuem K, et al. Moorfields AMD database report 2: fellow eye involvement with neovascular age-related macular degeneration. Br J Ophthalmol. 2020;104:684\u201390.","journal-title":"Br J Ophthalmol"},{"key":"2264_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000469652","volume":"238","author":"JK Chew","year":"2017","unstructured":"Chew JK, Zhu M, Broadhead GK, Luo K, Hong T, Chang AA. Bilateral neovascular age-related macular degeneration: comparisons between first and second eyes. Ophthalmologica. 2017;238:23\u201330.","journal-title":"Ophthalmologica"},{"key":"2264_CR22","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.ophtha.2014.04.026","volume":"121","author":"J Zarranz-Ventura","year":"2014","unstructured":"Zarranz-Ventura J, Liew G, Johnston RL, Xing W, Akerele T, McKibbin M, et al. The neovascular age-related macular degeneration database: report 2: incidence, management, and visual outcomes of second treated eyes. Ophthalmology 2014;121:1966\u201375.","journal-title":"Ophthalmology"},{"key":"2264_CR23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.4103\/tjo.tjo_35_18","volume":"9","author":"AH Palkar","year":"2019","unstructured":"Palkar AH, Khetan V. Polypoidal choroidal vasculopathy: an update on current management and review of literature. Taiwan J Ophthalmol. 2019;9:72\u201392.","journal-title":"Taiwan J Ophthalmol"},{"key":"2264_CR24","unstructured":"The Royal College of Ophthalmologists. Age Related Macular Degeneration Services Commissioning Guidance. 2021. https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2021\/07\/AMD-Commissioning-Guidance-Full-June-2021.pdf."},{"key":"2264_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.oret.2021.03.010","volume":"6","author":"S Aslanis","year":"2021","unstructured":"Aslanis S, Amr\u00e9n U, Lindberg C, Epstein D. Recurrent neovascular age-related macular degeneration after discontinuation of vascular endothelial growth factor inhibitors managed in a treat-and-extend regimen. Ophthalmol Retin. 2021;6:15\u201320.","journal-title":"Ophthalmol Retin"},{"key":"2264_CR26","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/OPTH.S269162","volume":"15","author":"MR Cheema","year":"2021","unstructured":"Cheema MR, DaCosta J, Talks J. Ten-year real-world outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration. Clin Ophthalmol. 2021;15:279\u201387.","journal-title":"Clin Ophthalmol"},{"key":"2264_CR27","doi-asserted-by":"publisher","unstructured":"Young SL, Ng N, Yap NJ, Hussain Z, Cackett PD. A novel multidisciplinary approach to the management of end-stage macular disease. Br J Vis Impair. 2021. https:\/\/doi.org\/10.1177\/02646196211032694.","DOI":"10.1177\/02646196211032694"},{"key":"2264_CR28","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/M15-0288","volume":"163","author":"WP Battisti","year":"2015","unstructured":"Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, et al. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Ann Intern Med. 2015;163:461\u20134.","journal-title":"Ann Intern Med"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02264-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02264-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02264-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T09:06:33Z","timestamp":1686906393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02264-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["2264"],"URL":"https:\/\/doi.org\/10.1038\/s41433-022-02264-3","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]},"assertion":[{"value":"22 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CB: Advisory board attendances for and honoraria from Bayer, Novartis, Alimera Sciences, Roche and Boehringer Ingelheim. PC: Advisory board attendances for and honoraria and travel grants from Bayer and Novartis; advisory board attendances for Roche and Allergan. AK: Advisory board attendances for Bayer, Allergan and Novartis; travel grants and speaker fees from Bayer and Novartis; research grant from Alimera Sciences. SM: Honoraria for lecturing and consulting and travel grants from Bayer and Novartis; principal investigator in multicentre research in conjunction with Bayer, Novartis and Roche. EM: Advisory committee participation for Bayer and Allergan-AbbVie; honoraria for presentations from Bayer, Allergan-AbbVie and Alimera Sciences; travel expenses from and conference attendances for Bayer, Alimera Sciences, Allergan and Novartis. NN: Advisory board attendances for and honoraria and travel grants from Bayer, Novartis and Roche. AP: Speaker honoraria and study leave grants from Bayer, Novartis, Alimera Sciences and Allergan; advisory board attendance for Bayer. DS: Speaker fees and advisory board attendances for Bayer, Novartis, Roche and Allergan; consultant for Big Picture Eye Health Ltd., Oculocare Ltd. and MTHK Ltd. PM-W: Employee of Bayer plc UK. CO: Employee of Bayer plc UK. KS: Employee of Bayer plc UK.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}